Company / R&D per Share
Prime Medicine, Inc. R&D per Share History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D per Share
$1.22
FY2025
5-year range
$1.22 / $5.44
FY2021-FY2025
Trend
-19.4%
vs FY2024
Sector context
#139 of 208
Health Care
What the data says
At $1.22, Prime Medicine, Inc.'s r&d per share ranks #139 of 208 in the Health Care sector. R&D per Share has declined for 4 consecutive years, from $5.44 in FY2021 to $1.22 in FY2025.
Based on SEC 10-K filings.
1.22 in FY2025 with a 5-year CAGR of +1.6%.
Declined from $1.63 to $1.22 over the past 2 years.
Health Care sector context is included.
R&D per Share over time
Growth rates
- 3-Year CAGR
- -22.9%
- 5-Year CAGR
- +1.6%
- 10-Year CAGR
- -
Sector benchmark
#139 of 208 in Health CareTop 67% of 208This company $1.22 Sector average $28.82
▼
-95.8% below sector average
Key checks
Key Insights
- Prime Medicine, Inc.'s r&d per share has declined for 4 consecutive years.
- In FY2025, r&d per share decreased 19.4% year-over-year.
- Ranks #139 out of 208 companies in the Health Care sector.
- Peak r&d per share was recorded in FY2021.
Company context
Key Data Points
- Altman Z-Score -3.54 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.22 | -19.4% |
| FY2024 | $1.52 | -6.6% |
| FY2023 | $1.63 | -39.2% |
| FY2022 | $2.68 | -50.8% |
| FY2021 | $5.44 | +381.7% |
| FY2020 | $1.13 | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026